ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

APGE Apogee Therapeutics Inc

41.14
0.00 (0.00%)
17 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Apogee Therapeutics Inc NASDAQ:APGE NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 41.14 39.34 42.79 0 01:00:00

Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02/01/2024 12:30pm

GlobeNewswire Inc.


Apogee Therapeutics (NASDAQ:APGE)
Historical Stock Chart


From Dec 2023 to Jun 2024

Click Here for more Apogee Therapeutics Charts.

Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that Michael Henderson, M.D., Chief Executive Officer of Apogee, will present at the 42nd Annual J.P. Morgan Conference on Tuesday, January 9, 2024 at 7:30 a.m. P.T. / 10:30 a.m. E.T.

A live and archived webcast of the presentation will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.

About Apogee Therapeutics

Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology indications with high unmet need. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering properties, including half-life extension. The company’s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit www.apogeetherapeutics.com.

Investor Contacts:

Noel KurdiVP of Investor Relations Apogee Therapeuticsnoel.kurdi@apogeetherapeutics.com

Media Contact:

Dan Budwick 1AB Mediadan@1abmedia.com

1 Year Apogee Therapeutics Chart

1 Year Apogee Therapeutics Chart

1 Month Apogee Therapeutics Chart

1 Month Apogee Therapeutics Chart

Your Recent History

Delayed Upgrade Clock